Allergy Therapeutics (AGY.L): Corp Profit upgrade | Aukett Swanke (AUK.L): Corp Interim results | Avacta (AVTG.L): Corp SARS-CoV-2 point-of care antigen test – update | discoverIE (DSCV.L): Corp Resilient, flexible and well positioned for growthiomart (IOMG.L): Corp Finals to March 2020 | Open Orphan (ORPH.L): Corp FY 2019 results
24 Jun 2020
Morning Note – 24 June 2020
discoverIE Group PLC (DSCV:LON), 738 | Allergy Therapeutics plc (AGY:LON), 19.8 | Avacta Group PLC (AVCT:LON), 136 | iomart Group plc (IOM:LON), 330 | Open Orphan Plc (ORPH:LON), 24.0
-
-
-
Andrew Darley | Guy Hewett | Mark Paddon | Mark Brewer | Michael Hill | Arshad Ahad
-
9 pages
-


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Note – 24 June 2020
discoverIE Group PLC (DSCV:LON), 738 | Allergy Therapeutics plc (AGY:LON), 19.8 | Avacta Group PLC (AVCT:LON), 136 | iomart Group plc (IOM:LON), 330 | Open Orphan Plc (ORPH:LON), 24.0
- Published:
24 Jun 2020 -
Author:
Andrew Darley | Guy Hewett | Mark Paddon | Mark Brewer | Michael Hill | Arshad Ahad -
Pages:
9 -
Allergy Therapeutics (AGY.L): Corp Profit upgrade | Aukett Swanke (AUK.L): Corp Interim results | Avacta (AVTG.L): Corp SARS-CoV-2 point-of care antigen test – update | discoverIE (DSCV.L): Corp Resilient, flexible and well positioned for growthiomart (IOMG.L): Corp Finals to March 2020 | Open Orphan (ORPH.L): Corp FY 2019 results